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Commercial nanopowders of MgB2 were characterized from the viewpoint of granulo-
metric distribution, structure, microstructure, and pH behavior in water. The powders are
very different: a higher amount of the MgB2 phase with a lower tendency for agglomeration
determines a higher rate of pH-increase. A higher rate of pH-increase usually produces a
stronger antimicrobial activity against Staphylococcus aureus, Enterococcus faecium, Escher-
ichia coli, Pseudomonas aeruginosa, Candida albicans, and Candida parapsilosis reference strains.
The variation of the pH-increase rate suggests the possibility of temporo-spatial control of
MgB2 bioactivity, although the contribution of other factors should not be neglected.
Remarkably, the efficiency of the MgB2 powders is higher against biofilms than onmicrobes
in the planktonic state. Further, our experiments confirm the antimicrobial efficiency of
MgB2 in the in vitro tests against 29 methicillin resistant clinical S. aureus isolates and 33
vancomycin resistant E. faecium/faecalis strains, but in this case the biofilms are more
resistant than planktonic cells. The MgB2 treatment of infected mice led to a significant
decrease of E. coli colonization in liver, spleen and peritoneal liquid and it also caused
changes in the intestinal microbiota. The activity of powders on HeLa and HT-29 tumor cell
lines was assessed by inverted microscopy, flow cytometry, and evaluation of the cellular
cycle. MgB2 inhibits tumor cell growth influencing DNA synthesis (S-phase). The obtained
results indicate that the tested powders could provide promising solutions for theP. Badica).
y Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
).
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and/or for anti-cancer therapies.
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Microbial infections remain one of the primary causes of
morbidity and mortality at global level. Therefore, they
represent a significant burden on well-being, health care
system, economy, and society, entailing continuous efforts
and costs for their eradication. Despite of the fact that highly
potent antibiotics and other antimicrobial agents were suc-
cessfully developed and are used today on a large scale, there
is a growing concern regarding the emergence of multidrug-
resistant microbial strains and of biofilm-associated in-
fections. Among the multiple reasons one can mention the
high diversity and fast adaptability of the microbial world,
increased selective pressure exhibited by the huge amounts of
antibiotics used not only for treating infections, but also in
livestock and agriculture, the co/cross-selection of antibiotic
resistance by other biocides, and the extended ability of mi-
crobial cells to adhere to different surfaces with formation of
highly resistant biofilms, which are responsible for 80% of the
human microbial infections [1]. To ensure complete healing,
the required antibiotic doses are significantly higher in the
case of biofilm-associated infections, the adherent microbial
cells being about 100e10,000 times less susceptible than
planktonic microbes.
Another leading cause of deathwith estimated 10.6million
cases by 2030 in the countries with low to medium human
development index is due to malignancies. Similar to micro-
bial infectious diseases, we are facing a crisis for the devel-
opment of new effective oncological drugs against the vast
majority of metastatic solid tumors [2]. For example, the
approval rate by US Food and Drug Administration (FDA) of
new oncological drugs is ~6.7% (2003e2011) which represents
about the half of the rate for the non-oncological drugs. The
time from the first regulatory filing of investigational appli-
cation of a new drug to its approval is relatively long and it is
estimated at 8.3 years [3,4].
Both microbial and cancer cells can exhibit inherited dif-
ferences that could generate resistance to treatment. The
resistance can be also acquired or fastened as a result of
prolonged drug treatment during disease progress or as a
consequence of other selective pressure agents. The resis-
tance mechanisms include: (i) mutational or epigenetic
alteration of the targeted protein of the drug; (ii) enzymatic
inactivation of the drug; (iii) bypassing of the target; (iv) pre-
venting drug access to targets. Noteworthy is that some an-
tibiotics may exhibit antitumor features, justifying the
introduction of the term antineoplastic/antitumor antibiotics
(e.g., cisplatin, carboplatin, and oxiplatin, bleomycin, ene-
diynes, and mitomycin acting quite similar as quinolones by
inhibiting the DNA replication and cellular multiplication)
[5,6]. The indicated common features suggest that as apromising approach to increase the chance of discovering new
solutions to pharmacological resistance is the search for po-
tential drugs with multi-pharmacological action, in our case
antimicrobial and antitumor.
Many studies indicate on highly efficient antimicrobial
activity of nanomaterials (NM) [7e12]. The advantage resides
in their different mode of action comparatively to antibiotics.
Most antibiotics (excepting beta-lactams, bacitracin and gly-
copeptides) act from inside the cell, while NM are active
through the contact with the bacterial or fungi cell wall,
without the need for penetration of the cell. Therefore, the
chemotherapeutic effect of NM is driven by processes that
take place at the interface and two major lethal groups of
interdependent mechanisms are presented in literature [7,8]:
(i) disruption/damage of membrane integrity and potential:
NM bind electrostatically the wall, producing membrane de-
polarization with the loss of integrity that will lead to the
disturbance of different metabolic cell functions such as
transport, respiration, and energy transduction. All these ef-
fects result in cell lysis and eventual death [11]; (ii) production
of reactive oxygen species, ROS (the most common are 1O2,
O2
Cd, H2O2,
COH, OHd; others are HOCl, ROOC, HOOC,
ONOOd, NO, CNO2) [13], far away from an optimum level
reached during the cellularmetabolism. At low doses, ROS can
cause severe DNA damage and mutations, while at higher
concentration, ROS lead to the imminent cell death, caused by
the severe oxidative stress and macromolecules modification
via lipid peroxidation, alteration of proteins, inhibition of
enzymes, and RNA and DNA damage [13,14]. NM that influ-
ence ROS production through catalytic action are described by
Haber/Weiss- and Fenton-type reactions [13,14]. Apart from
these mechanisms, NM were found in some cases to induce
programmed cell death, production of reactive nitrogen spe-
cies (RNS), and direct inhibition of essential enzymes [7].
Despite the fact that NM are promising antimicrobial candi-
dates, the strategies of their development are of high
complexity considering the high diversity of microbes (taxo-
nomic or morphological type, planktonic or biofilm, growth
rate, starved or stationary, etc.) and of materials (type and
composition/concentration/impurities, particle size and
morphology, surface state, roughness, crystal-chemistry de-
tails, processing history, etc.) [15e20]. The sensitivity of mi-
crobes to the lethal action of NM depends also on many
environmental factors such as contact time, pH, aeration, and
temperature. Presented situation points on the necessities
and challenges in the field. Namely, the design of multifunc-
tional and multicomponent antimicrobial tools acting effec-
tively on a wide range of microbes in very different
environment conditions is a priority. To address it, the
multicomponent antimicrobials or hybrid combinations of
NM with antibiotics are thought as one promising direction
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enhanced antimicrobial activity, but with less toxicity to
humans. NM could be used as active materials replacing the
bioinert ones in many biomedical devices and they are also
expected to contribute to the development of oncologic drugs
for fighting cancer.
Antimicrobial materials presented in literature are often
metals, oxides, and polymers. Some strategies in developing
technologies to reduce infections associated with polymer
surfaces are reviewed in ref. [21]. Natural products extracted
from microbes, plants and animals with antimicrobial effect
are also gaining in popularity [20,22e24]. Elements with anti-
bacterial activity are Ag, Cu, Zn, Mg, Ce, Ti, Al, Si, Au, Bi, Ca, Fe,
Pt [8] and in many cases their oxides are used [8]. This may be
justified by the negatively charged cellular wall [25] that is in
opposition with the positive ions provided by the metals and,
if using oxides, with the presence of extra or deficient oxygen
potentially interfering with ROS mechanisms. As biocompat-
ibility is an important feature for biomedical NM, some of the
elements and oxides such as ZnO and MgO are very advan-
tageous, as they provide essential elements for the human
health. From a different perspective, NM are also considered
in new strategies for cancer treatment, acting either directly
as antitumor agents (e.g., as stimulants of free radicals
release) or indirectly, as co-adjuvants for other anticancer
treatments (e.g., radiation) and as pharmaceutical carriers to
enhance the in vivo efficacy of antitumor drugs, assuring tar-
geted drug delivery and controlled release [26].
MgO was reported to exhibit antibacterial activity [27e29].
Its efficiency was found to be higher against Gram-positive
than against Gram-negative bacteria [30e34]. Responsible for
the antibacterial activity are considered oxygen defects (va-
cancies) from the surface of MgO nanoparticles (NP). A strong
lipid peroxidation and ROS generation [27,30,31,35e40] are
inferred. Some reports also point on deathmechanisms based
on direct contact between NP and the cell. Namely, the cell
membrane damage is induced by the alkaline effect, where NP
play an important role [30,31,40,41]. Supporting experiments
are those in which it is shown that the bactericidal efficiency
depends on the particle size and aggregation of MgO NP
[29,42,43]. Moreover, it was claimed that themainmechanism
of the cellular death is not lipid peroxidation [41], but NP
attachment to microbes play an essential role. This can
involve phosphate groups from the surface of the cell [41] and
the halogen elements absorbed on the surface of the NP in the
presence of water. According to ref. [44] the layer of water
formed between NP and cell contributes to local changes in
the alkalinity. These differences promote membrane damage
leading to accelerated cell death of vegetative forms of bac-
teria and endospores [45,46]. This principle was further
employed. Magnesium halogens particles (MgBr2, MgCl2,
MgF2) have shown the ability to impede growth and biofilm
formation of pathogens such as Escherichia coli, Staphylococcus
aureus, Bacillus megaterium, and Bacillus subtilis [12,30,47e50].
MgF2 was used to fabricate modified catheters [48]. Superior
activity was found also for other Mg-containing NM, e.g.
composites of MgO/ZnO [34,51], MgO/nisin [51], and CaCO3/MgO [39]. The Mg(OH)2 [52] and Mg-doped hydroxyapatite [53]
were also found to be antibacterial agents. MgO was also
demonstrated as an antifungal compound [54,55].
Other elements and compounds with antimicrobial activ-
ity are non-metals such as C [56] and B [57]. According to
World Health Organization (WHO) [58], boron plays an
important role in the metabolism of humans [59]. Boron is
involved in steroid hormone metabolism, healthy bone
growth, and cell membrane care [60e63]. Boron improves the
wound and burn wound healing [64,65]. In healthy people
boron levels are 15e80 mg/kg [66], and an intake of 1e7 mg
boron is considered safe [57]. Boron is present in the body as
boric acid and it is completely absorbed from gastrointestinal
tract [67]. The biocompatibility of boron is doubled by its
antiseptic, bactericidal, insecticidal, herbicidal and cleaning
(used in detergents) functions when it is in the form of boric
acid and sodium salts of boron (borax, disodium tetraborate).
Boron is contained in the antibiotic boromycin (produced by
Streptomyces antibioticus) acting on Gram-positive bacteria [68],
in bacterial antibiotics tartrolons (produced by Sorangium cel-
lulosum) [69,70], borophisin, aplasmomycin (produced by
Streptomyces griseus) [71e73] and in the bacterial quorum
sensing molecule autoinducer AI-2 [74]. Boric acid is used in
treatment of the vaginal yeast infections especially caused by
Candida albicans [75], acting through the disruption of the hy-
phal growth by impairing the actin organization in yeasts [76].
Concerning cancer, boric acid has shown positive effects
against human prostate cancer cells [61,77,78] and phenyl-
boronic acid was found to be an inhibitor of the cancer cell
migration [79,80]. Boron reduces the risks of lung and breast
cancers in women [81,82]. Boric acid has been found to protect
DNA against carcinogenic oxidative damage caused by
aflatoxin B1 [76,83], which can be found on food contaminated
by the fungus Aspergillus.
From previous two paragraphs it results that compounds
with B and Mg in the view of their biocompatibility and
biocide functions and of their interconnected involvement in
the metabolic processes from the human body can be of
much interest for biomedical applications. In ref. [84], MgB2
was found to lethally act against E. coli ATCC 25922 and S.
aureus ATCC 29213 bacteria. In this work we confirm previous
results and expand the range of tested microbes. We
demonstrate the biocidal activity of MgB2 on eukaryotic
Gram-positive (S. aureus ATCC 25923, S. aureus ATCC 6538,
Enterococcus faecium DMS 13590) and Gram-negative (E. coli
ATCC 25922, Pseudomonas aeruginosa ATCC 27853) bacteria
strains as well as on yeasts (C. albicans ATCC 10231, C. para-
psilosis ATCC 22019) in planktonic and biofilm state.
Furthermore, we evaluate the antimicrobial efficiency of
MgB2 in the in vitro test against 29methicillin resistant clinical
S. aureus isolates and 33 vancomycin resistant E. faecium/
faecalis strains and in the in vivo experiments using CD1 mice
model infected with E. coli. The activity of MgB2 on HeLa and
HT-29 tumor cell lines is also presented. The four commercial
MgB2 nanopowders used in our experiments show specific
features that influence their antimicrobial and antitumor
behavior.
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2.1. MgB2 powders and characterization methods
Raw nanopowders of MgB2 were supplied by LTS Research
Laboratories Inc (LTS), Pavezyum Advanced Chemicals (PVZ),
Alfa Aesar (AA), and CERAC Inc (CER) part of Materion -
Advanced Materials Group. The purity (metal basis) of the
powders is presented in Table 1.
The granulometric distribution of the powders was
measured with Fritsch Laser Particle Sizer Analysette 22. The
measurement was found to stabilize after 3e5 attempts.
The pH evolution vs. time of MgB2 water suspensions was
measured with a pH sensor (±0.2 accuracy) and a 12-bit data
acquisition system, at ~28 C. A quantity of 0.1 g MgB2 powder
was poured through a 5mmdiameter plastic straw into 50 mL
waterwith a starting pH of ~7.5. The powderwas poured at the
same distance from the pH sensor in order to provide similar
experimental conditions. Suspensions with MgB2 powders
were slowly stirred with a crossed-blade impeller at 19 rpm.
X-ray diffraction patterns were takenwith a Bruker AXS D8
Advance diffractometer (CuKa radiation). By using Rietveld
analysis (MAUD 2.31 [85]) we determined the weight fraction
of the phases, a and c lattice parameters of MgB2, the crys-
tallite size, and the residual strain (Table 1). The carbon
amount (denoted y, Table 1) substituting boron in the crystal
lattice of MgB2 [Mg(B1-yCy)2] was calculated with the empirical
formula:
y ¼ 21.9$a þ 6.76 (a in nm) (1)
considering mediated data from refs. [86e88].
The microstructure of the powders was investigated by
scanning electron microscopy (SEM, Lyra 3XMU/Tescan).
Transmission electron microscopy (TEM) observations were
performed with JEM 2100 microscope. The TEM is equippedTable 1 e Samples, purity according to suppliers, a and c lattic
microstrain (m) of MgB2, FWHM (full width at half maximum) o
crystallite size. Phase identification was performed based on IC
and ICDD 35e0821 (Mg).
Sample Purity (metal basis), [%] MgB2 lattice
parameter, a [A]
LTS 99.5 3.0863 ± 0.0001 3
Pavezyum,
PVZ
>95 (not specified if metal basis or not) 3.0851 ± 0.0001 3
Alfa Aesar,
AA
99 3.0861 ± 0.0002 3
Cerac, CER 99 3.0850 ± 0.0001 3
Sample Phase amount [wt. %]
MgB2 MgB4 MgO
LTS 97 ± 0.5 0 1.8 ± 0.2
Pavezyum, PVZ 94.6 ± 0.5 3.0 ± 0.5 1.3 ± 0.1
Alfa Aesar, AA 88.0 ± 1 7.1 ± 0.8 4.6 ± 0.7
Cerac, CER 80.3 ± 0.5 11.8 ± 0.5 7.9 ± 0.3
Note: In sample PVZ a small peak at 2q ¼ 26.5 was detected and ascribewith ASTAR crystallographic analysis module which was
successfully used for identification of single crystal and
polycrystalline powder particles. The TEM was also equipped
with the polar setup for tomography measurements. Acqui-
sition of the images and reconstruction of the 3D volume from
the tilt series was performed using JEOL proprietary and open-
source software (tomo3d, IMOD, Fiji).
2.2. Antimicrobial activity of MgB2 powders
The four types of raw MgB2 nanopowders (LTS, PVZ, AA, and
CER) were tested in two steps:
(1) in the first step, the antimicrobial and anti-biofilm ac-
tivity was assessed qualitatively for their antimicrobial
activity against susceptible reference strains: S. aureus
ATCC 25923, S. aureus ATCC 6538, P. aeruginosa ATCC
27853, E. coli ATCC 25922, and yeasts C. albicans ATCC
10231, C. parapsilosis ATCC 22019, in planktonic and
biofilm growth state. For antimicrobial susceptibility
testing, the microbial strains were routinely cultivated
on Tryptone Soy Agar (TSA) (bacteria) and Sabouraud
agar (yeasts);
(2) in the second step, the efficiency of the tested powders
against clinical, resistant S. aureus strains in planktonic
and biofilm growth state was measured by quantitative
assays. The study was conducted on a total number of
60 strains isolated from ambulatory and hospitalized
patients, out of which 29 were of S. aureus strains iso-
lated from different clinical sources, mostly from sur-
gical wound secretions, urine, respiratory tract
secretions, blood cultures and 31 were of E. faecium and
E. faecalis strains isolated from surgical wounds secre-
tions and urine.
The qualitative testing of MgB2 antimicrobial activity was
performed by an agar diffusion adapted method. For thise parameters of MgB2, carbon amount (y) in Mg(B1-yCy)2,
f the MgB2 XRD peak at 2q ¼ ~60, phase content, average











.5221 ± 0.0001 0.0011 ± 0.0003 0.075 0.18
.5210 ± 0.0001 0.0037 ± 0.0006 0.097 0.39
.5249 ± 0.0001 0.0015 ± 0.0007 0.098 0.20
.5235 ± 0.0001 0.0039 ± 0.0005 0.107 0.22
The average crystallite size from XRD [nm]
Mg MgB2 MgB4 MgO Mg
1.2 ± 0.1 113 ± 5 e 45 ± 2 51 ± 30
1.1 ± 0.1 42 ± 2 37 ± 4 31 ± 2 35 ± 20
0.3 ± 0.1 113 ± 5 100 ± 7 31 ± 3 91 ± 50
0 105 ± 4 68 ± 5 41 ± 2 e
d to graphite impurity (ICDD 56e0159).
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microbial suspensions prepared in sterile physiological water
with a density corresponding to the 0.5 McFarland nephelo-
metric standard. Suspensions were made from fresh cultures
grown for 24 h at 37 C on agar medium. Then, suspensions
(10 mL) of each MgB2 powder prepared in dimethyl sulfoxide
(DMSO) with a concentration of 10 mg/mL were added in spot
on the inoculated plates. For reference, DMSO was also added
in spot in the same volume. Plates were incubated at room
temperature until total absorption of the deposited solution.
After that, they were incubated for 24 h at 37 C. Clear mi-
crobial growth inhibition areas were recorded as evidence for
the presence of the antimicrobial activity of the stock MgB2
suspensions. The diameter of these inhibition zones was
measured with a ruler and expressed in mm.
In the quantitative test, the minimum inhibitory concen-
tration (MIC) of the MgB2 of the raw powders was tested by
broth microdilution method in liquid medium (Mueller Hin-
ton), using 96-well plates. Binary serial dilutions of the stock
MgB2 suspensions were prepared in a volume of 100 mL of
DMSO (concentration range of 2500 mg mL1 to 4.9 mg mL1).
Subsequently, the wells were seeded with 20 mL of McFarland
0.5 (1e2$108 UFC/mL) microbial suspensions. The positive
control was represented by the untreated microbial culture,
and the negative control by the sterile culture medium. After
incubating the plates at 37 C for 24 h, growth inhibiting ac-




Fig. 1 e SEM images of MgB2 powders. Magnification increases fr
backscattering mode and all the others in the secondary electro
arrows.concentration of MgB2 solution corresponding to the last well
in which the development of the microbial culture was no
longer observed represented the MIC value (mg/mL) for the
tested powder type.
After reading the MIC, the protocol was continued to
establish theminimal biofilm inhibitory concentration (MBIC).
For this purpose, the 96-well plates used for determining the
MICwere emptied andwashed twicewith sterile physiological
water to remove the planktonic cells. Then, the remaining
cells adhering to the plastic walls of the wells were fixed for
5 min with 130 mL of 80% methanol and then stained with 1%
crystal violet alkaline solution (130 mL/well) for 15 min. The
microbial biofilms were then resuspended in 33% acetic acid,
and the intensity of the colored suspension was assessed by
reading the absorbance (A) at 492 nm with an Apollo LB
911ELISA reader. The lowest concentration corresponding to
an A-value lower than that of the growth control and similar
to that of the negative control was considered to be the MBIC.
2.3. In vitro cytotoxicity assays
To evaluate the in vitro interaction between the powder sam-
ples and human cells, two tumor cell lines were used, namely
HeLa and HT-29. HeLa (cervical cancer) and HT-29 (colon
adenocarcinoma) cells were seeded into 24-well plates at a
density of 1$105 cells/well and cultivated in modified Dulbec-
co’s medium (DMEM: F12) (Sigma, USA) supplemented withom left to right. Images from the first columnwere taken in
ns regime. 1D dendritic grains in PVZ are indicated with
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at 37 C, in a humid atmosphere with 5% CO2. Subsequently,
the cells were treated with binary serial dilutions of MgB2
powders starting at 100 mg/mL and incubated for another
16e24 h under the same conditions. After the treatment
period, the cells were stained with 100 mg/mL fluorescein
diacetate (FDA) and 50 mg/mL propidium iodide (PI) for 5min at
37 C. The plates were visualized using an Observer D1 Zeiss
microscope (l ¼ 546 nm).
The cell cycle analysis in a DNA contentmeasurement was
performed by flow cytometry [89]. Cells were inoculated in 96-
well Multiwell plates, and maintained in DMEM (Dulbecco’s
Modified Eagle Medium): F12 medium (Gibco), supplemented
with 2% fetal bovine serum, 1% glutamine, 1% penicillin-
streptomycin, 1% fungizone at 37 C, in a humid atmosphere
with 5% CO2, until the monolayer has reached a 80e100%
confluence. The cells treated with 100 mg/mL MgB2 solutions
were maintained at 37 C in a humid atmosphere with 5% CO2
for 16 h. Cells were trypsinized, washed in phosphate buffered
saline (PBS) and fixed in 1 mL of cold 70% ethanol for at least
30 min at 20 C. Cells were washed in PBS, resuspended in
100 mL PBS, treated with RNase A (final concentration 1 mg/
mL) at 37 C for 30 min and stained with propidium iodide (PI,
final concentration 100 mg/mL) for 30 min at 37 C, with peri-
odic stirring. The samples were measured on a Beckman
Coulter XLM flow cytometer and analyzed with the FlowJo
software.
2.4. In vivo infection model to confirm the antibacterial
activity of MgB2
Nude mice, type CD1 (16 females, 6e8 weeks old), were used
to determine the in vivo antimicrobial activity of MgB2 as
well as its influence on the intestinal microbiota. The ani-
mals were placed in individual ventilated cages. Animal
care practices adapted to local conditions and following EU
regulations (EU Directive 2010/63/EU for animal experi-
ments) were applied to minimize the risk of contamination
and stress induced by the experiments. The experimental
groups of animals were monitored, and conditions were















Fig. 2 e Granulometric curves of MgB2 powders: (a) as measure
corresponding to the smallest mean particle size.behavior were observed. The groups, each consisting of 4
animals, were:
(1) control mice, without infection and untreated with
MgB2;
(2) mice infected with E. coli;
(3) mice without infection and treated with MgB2
(LTS powder);
(4) mice with infection and MgB2 (LTS powder) treatment.
The LTS powder was selected considering its high
antibacterial activity (see section Results).
The uropathogenic E. coli 424 strain from the Research
Institute of the University of Bucharest microbial collection
was used for infecting the animals from the experimental
groups (2) and (4). The bacterial culture grown in liquid
medium for 18e24 h was centrifuged (5 min, 3500 rpm) and
the pellet was resuspended in PBS at a density of 1 McFar-
land. The as-obtained suspension was administered intra-
peritoneally (200 mL/mouse). After 2 h, the MgB2 powder
(2 mg) in PBS (200 mL) was administered by gavage to group
(4). The animals were carefully monitored daily. Four days
after infection, animals were sacrificed by cervical
dislocation.
For microbiological analysis, liver, spleen, and intraperi-
toneal fluid were extracted (mice from groups 2 and 4) and the
E. coli load was quantified by culturing on Tryptone Bile
X-Glucuronide (TBX) selective medium. Abundance was
expressed as colony forming units (CFU) per gram of tissue
(CFU/g).
The experimental groups (1) and (3) were analyzed to study
the effect of MgB2 on the murine intestinal microbiota. Sam-
ples from healthy mice populations (group 1) and MgB2-
treated (group 3) were used for DNA extraction with a com-
mercial kit (Fast DNA Stool Mini kit, Qiagen). The as-obtained
DNAwas diluted to a concentration of 3 ng/mL and subjected to
real-time polymerase chain reaction (PCR). Specific primers
for 16 S rRNA were used for different bacterial cells such as
Enterobacteria, Lactobacilli, Ruminococcus and Clostridium leptum/
coccoides.
For statistical analysis, sample size (n ¼ 4) denotes the
















d and (b) normalized to the value of the maximum
j o u r n a l o f ma t e r i a l s r e s e a r c h a nd t e c hno l o g y 2 0 2 1 ; 1 2 : 2 1 6 8e2 1 8 42174GraphPad Prism 5.0 software and statistical analyses were
performed considering the unpaired t-test. Statistical signifi-
cance (p) depends on experiment (Fig. 8).3. Results and discussion
3.1. MgB2 powders characterization: structural,
microstructural, granulometric, and pH
Results of structural analysis on MgB2 powders are presented
in Table 1. Powders are composed of the main phase MgB2,
plus MgB4, MgO, and Mg as secondary phases. Powders were
ordered top-down in Table 1 for the decreasing amount of
MgB2 as follows: LTS, PVZ, AA, and CER. A similar decreasing
trend is observed for Mg, while an opposite (increasing) one
was found for MgB4 and MgO (exception is the low value of
1.3 wt. % for MgO in PVZ). No MgB4 and Mg were detected
through XRD in LTS and CER, respectively. The powders LTS
(113 nm), AA (113 nm) and CER (105 nm) have similar crys-
tallite size, while in PVZ the crystallite size is more than 2
times lower (42 nm). A higher carbon amount y (yCER > yPVZ >-
yAA > yLTS) is approximately accompanied by larger micro-
strain (mCER > mPVZ z mAA > mLTS) and FWHM
(PVZ > CER >AA > LTS) values. Exception is the highest FWHM
value for PVZ among all the powders, almost double than for
the other powders. The provided values of y are semi-
quantitative, they are used only for a relative comparative
analysis among the samples, and they should not be regarded
as absolute values. However, the values of y are considered
extremely low and they correspond to a lightly substituted,
almost pure, MgB2. Hence, the impact of y-carbon on bioac-
tivity of our MgB2 powders is expected to be negligible. The
results point on difficulties related to XRD assessment of
nanopowders but may also suggest special features for the
PVZ powder due to its large FWHM. Traces of graphite were
observed by XRD only for PVZ sample (Table 1, see Note) and
this powder has the lowest purity (Table 1). In addition, one
observes that in PVZ powder the crystallite size variation
among all phases is narrow with ratio R between the
maximum and the minimum average crystallite sizes being
42 nm (MgB2)/31 nm (MgO) ¼ 1.35. For the other powders, ratio
R is significantly larger: 2.51 in LTS, 3.64 in Alfa Aesar and 2.56
in CER. From this comparison, AA is at the opposite end of R-
values to PVZ sample. The very different structural features
anticipate a very different behavior of powders
agglomeration.Table 2 e Diameters of microbial growth inhibition zones, as r
efficiency (E) is for a larger diameter of the inhibition region.
Sample Gram-positive bacteria
S. aureus ATCC 25923
(SA) (mm)








DMSO e eSEM images taken with increasing magnification are
shown in Fig. 1.
On a large scale (small magnification, first 2 columns from
the left in Fig. 1), the CER powder is the most uniform in
respect to agglomerates. The next powders in uniformity of
agglomerates are LTS and PVZ. At intermediate magnifica-
tions (columns 3e5 in Fig. 1) one observes that for sample LTS,
AA, and CER the agglomerates size is mostly in the range of
5e30 mm. The PVZ powder is an exception. It contains many
large agglomerates some of them up ~60 mm. A closer look on
the agglomerates at high magnifications (columns 6 and 7,
Fig. 1) indicates that they are composed of particles, individual
or bound into some units (groups). In all powders, some
groups of 0.5e3 mm are apparently bonded and form a grain.
Particles are roughly around 100 nm and this is in good
agreement with the average crystallite size determined from
XRD. Particles and groups/grains often show an irregular 3D
shape. In PVZ powder, some groups/grains are rather 1D and
generate a dendritic-like appearance (Fig. 1, PVZ, see the ar-
rows). However, the incidence of 1D grains is low. To observe
the morphology of the particles and the grains in detail, TEM
investigationswere employed and results are presented in the
next paragraphs.
In the granulometric curves (Fig. 2a) measured for soni-
cated samples (<200 W) in which a dispersing agent was
added, two major fractions were revealed. The fraction
comprised of large particles corresponds to agglomerates
from SEM observations. Namely, a maximum is reached for a
mean particle/aggregate size of ~15 mm in powders LTS, AA,
and CER. For PVZ sample, the peak is significantly larger
spanning from 5 to 67 mm: A maximum is located at 23 and a
shoulder occurs at 35 mm. The granulometric fraction
composed of small particles/aggregates shows a maximum
around 1e2 mm and corresponds to units defined as grains in
SEM. The good agreement between SEM and granulometric
data indicate on high stability of the agglomerates. They are
not broken by typical ultrasonic processing. When granulo-
metric curves are normalized (Fig. 2b) to the value of the
maximum (in %) for the fraction composed of small particles,
one can observe how strong is the relative aggregation into
large-size agglomerates. The strongest relative aggregation is
for PVZ followed by CER, AA and LTS. High energy sonication
(Fig. 2, curve LTS ultrasonicated) beyond 600 W breaks the
agglomerates and the granulometric curve changes its shape.
It remains bimodal with the peak for small sizes being more




E. coli ATCC 25922
(Ec) (mm)
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larger than 2 mm.
Results of TEM investigations are presented in Fig. 3. A
general observation is that particles’ morphology is mostly of
two types: plate-like hexagonal and 3D irregular shapes. In
PVZ powder, 1D-like grains (Fig. 3 PVZ-a) were observed,
confirming the dendritic-like grains revealed by SEM. Parti-
cles of MgeBeO with a bar-like morphology and sizes be-
tween 50 and 300 nm are shown in Fig. 3 CER-d. Plate-like
particles can reach an in-plane size up to 500e800 mm in AA
powder (Fig. 3 AA-f). Plate-like particles with sizes around
100e150 nm were often found in CER sample (Fig. 3 CER-a).
Electron diffraction mapping of plate-like grains demon-
strate that each grain is a single crystal (Fig. 3 AA-e). Grains
with irregular 3D shape (<500 nm) were observed by to-
mography (Fig. 3 LTS-e, AA-g-i, CER-b, c). Some surfaces are
flat and between the edges, the angles are often of 60 and
120. Some angles are 90 (Fig. 3 AA-g-grain on the left and i-
grain in the center). MgB2 has a layered hexagonal crystal
structure. Mg is also hexagonal, but its amount is low in the
samples. The other phases identified by XRD have different
crystal structures. MgB4 is orthorhombic and MgO is cubic.
Therefore, presented information suggests that grains with
irregular shape might be composed of different phases in the
MgeBeO system (grains with angles of 60 and 120 can be
mainly ascribed to MgB2, while the grains with 90 angles
may belong to other phases). Based on XRD, the CER sample
contains the highest amount of MgB4 (Table 1). By TEM/EDS
(Fig. 3 CER e-m) some grains show a B/Mg ratio close to 4
(usually 4.4e4.75) and they were ascribed to phase MgB4
(Fig. 3 CER e-point 2, k). Stoichiometric compositions as for
MgB2 were measured (B/Mg ¼ 2, Fig. 3 CER d), but keeping in
mind limitations due to sample thickness, some composi-
tions deviate and the scattering range in CER sample is B/
Mg ¼ 1.44e2.2 (Fig. 3 CER e-points 1 and 3, j, m). We could
not find boron-rich compositions as for higher boride phases
(MgB7, MgB12, MgB19, B). Apparently, the amount of these
phases in the powders is low as also inferred from the XRD
measurement. The MgO compositions were found especially
if the investigated oxygen-rich regions were with a relatively
large size (see e.g. Fig. 3 e, f, i, grain on the top left corner). It
is worth noting that some edges of MgB2 grains are not
straight, possibly indicating on synthesis processes with gas
or liquid phases. Some surfaces depart from a flat and clean
(i.e. not contaminated) state. While in LTS, AA, and CER
samples surfaces with enhanced roughness are still rela-
tively clean, in PVZ powder (Fig. 3 PVZ-a-e) EDS maps indi-
cate a strong contamination with oxygen for both plate-likeFig. 3 e Transmission electronmicroscopy results for investigate
O, (e)- tomography image of an agglomerate made of 3D irregu
overlapping (c)-(e)- EDS maps of elements. AA: (a)- image, (b)- R
elements, (e)- tomography image of a plate like particle, (f)- TEM
image of an agglomerate made of 3D irregular particles observe
image of plate-like MgB2 particles, (b) and (c) tomography image
bar-like grains shown in the inset (B/Mg ¼ 2.06), (e)- TEM image
spectra (j), (k), (m) measured on locations indicated with 1e3 and
image formed by overlapping (g)-(i)- EDS maps of elements.and irregular 3D particles. For PVZ, MgB2 is in most cases
covered by an oxide layer that forms a shell.
The morpho-structural differences between powders
impact rheological, dispersion and solubilization in liquids,
pH, and other properties. For example, PVZ shows the
highest flowability, while LTS has the lowest one. The
explanation is that although PVZ has the lowest crystallite
size and expectations are for low flowability, it forms the
largest aggregates, it contains free graphite, and the surface
of the particles is passivated by oxides. All these features
will favourably contribute to high flowability. For LTS, low
flowability can be explained by the lowest level of
agglomeration and the absence of the contaminated sur-
faces. The features of the powders are important not only
technologically, but they also affect the powderecell inter-
action. The biochemical interaction depends on pH, among
other parameters. In this respect, we investigated the pH of
the four studied powders immersed in water. Saturation
values of pH (Fig. 4) are within a narrow range (9.9e10.1
after 180 min), but kinetics details are different. The in-
crease rate of pH is the highest for LTS, followed by PVZ,
AA, and CER. Although different features of the powders
may influence evolution of pH, the increase rate apparently
correlates with the amount of MgB2 phase in the powders
(Table 1). This result suggests the possibility to view MgB2
materials as solutions for space and time-scale controlled
variation of the functional properties required for different
bio-applications. Nevertheless, water degradation of MgB2
powders is a complex process. According to reaction (2) [90]
the main product is Mg(OH)2 with a low solubility (0.0009 g/
100 mL H2O g/L):
MgB2þ2H2O/Mg(OH)2Yþ2B þ H2[ (2)
The Mg(OH)2 phase precipitates and may passivate the
MgB2 source particle, impeding further development of the
reaction. The Mg(OH)2 also forms in the reactions (Eqs. (3)e(5))
between MgB4, MgO or Mg [91] with water:
MgB4þ2H2O/Mg(OH)2Yþ4B þ H2[ (3)
MgO þ H2O/Mg(OH)2Y (4)
Mgþ2H2O/Mg(OH)2Y þ H2[ (5)
On the other hand, the hydroxide passivation effect is
hindered by hydrogen release in reactions (2), (3) and (5).
These processes are multistep, overlapping, and possiblyd powders. LTS: (a)- image, (b)e(d) - EDSmaps of B, Mg, and
lar particles. PVZ: (a)- image, (b)- RGB image formed by
GB image formed by overlapping (c)-(d)- EDS maps of
image of plate-like MgB2 particles, (g)-(i)- tomography
d from carthesian directions (top, side, front). CER: (a)- TEM
s of 3D irregular grains, (d)- typical EDS spectra taken on the
on which were taken EDS maps of elements (g)e(i) and EDS
with B/Mg ratio of 1.44, 4.59, and 1.75, respectively; (f)- RGB
Fig. 4 e Evolution of pH vs. time for MgB2-water
suspensions.
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were investigated theoretically in ref. [91] and theywere found
to develop in amultistep sequence. The reaction barrier for (4)
was estimated to be lower than for (5), and the mechanism is
simpler in reaction (4) than for reaction (5). It was concluded
that MgO is the first to react with water rather than Mg. At the
same time, MgO is slightly soluble in water (6.2  103 g/l [92]),
and has a higher solubility of 8.6  102 g/L in physiological
solutions [93]. The addressed aspects draw attention on the
necessity of a careful assessment of the MgB2 materials in
controlling the alkalinity and their biological impact. It in-
dicates that the use of the correlation between pH increase
rate and the MgB2 amount must be considered only as a
reference point in designing biomaterials, and a case-by-case
approach should be applied. As it will be presented in the next
sections, the biointeraction departs from the MgB2 phase - pH
correlation, and other factors of processing, materials (e.g. the
influence of elemental and phase impurities, microstrain and
defects), and cells must be revealed and controlled. For
example, y-carbon, through associated micro-strain, is ex-
pected in heavily doped samples to modify decomposition of
MgB2 in water, its pH-behavior, and, ultimately, its bio-
interaction. However, at present, authors are not aware of
any reported experiments on this topic and at least powders
LTS, AA and CER qualify as sampleswith a very low amount of
carbon.Fig. 5 e Minimum inhibitory concentration measured on microb
¼ Staphylococcus aureus ATCC 25923; SA1 ¼ Staphylococcus aure
Ec ¼ Escherichia coli ATCC 25922; Ca ¼ Candida albicans ATCC 1In summary, this section provides comparative informa-
tion on physico-chemical features of the MgB2 powders.
Morpho-structural details are very different. This statement is
true both at nano and micro scales. The pH saturation values
in water of these powders in solution are between 9.9 and 10.1
and kinetics to reach these values is different among the
powders. The pH-increase rate is primary influenced by the
amount of MgB2 phase in the powders, but other factors
should be also considered. Hence, the degree of complexity is
high and this will be reflected on the relatively low predict-
ability regarding the powders behavior when in contact with
the cells.
3.2. Antimicrobial activity of MgB2 powders
3.2.1. Antimicrobial activity of MgB2 powders against
susceptible, reference strains in planktonic and biofilm growth
state
The result of qualitative screening by the agar diffusion
method (Fig. 1 Supplementary) of MgB2 powders reveals that
all tested samples exhibit an inhibitory activity against
different microbial reference strains. The best results (largest
diameters) are obtained for LTS and CER (Table 2). However,
the antimicrobial efficiency (E, expressed in mm) of the four
powders depends on microbial strains, i.e. for S. aureus ATCC
25923 (SA) ELTS ¼ EPVZ ¼ EAA > ECER, for S. aureus ATCC 6538
(SA1) ECER > ELTS > EPVZ ¼ EAA, for P. aeruginosa ATCC 27853 (Ps)
ECER ¼ EAA > ELTS > EPVZ, for E. coli ATCC 25922 (Ec) ECER >-
ELTS > EPVZ ¼ EAA, and for Candida albicans ATCC 10231 (Ca)
ELTS ¼ EPVZ > EAA > ECER.
The scattering (S) of efficiency (S ¼ Emax-Emin) shows the
following decreasing order: SCER¼ 13mm> SAA¼ 5mm¼ SPVZ-
¼ 5 mm > SLTS ¼ 4 mm. This indicates that LTS has the most
uniform antibacterial effect and depends less on the tested
microbes.
The MIC and MBIC values are presented in Fig. 5. The
highest efficiency, i.e. the lowest values of MIC andMBIC were
recorded for LTS (0.31e0.62 mg/mL and 0.039e0.62 mg/mL,
respectively) in good agreement with qualitative test results.
Remarkable is that MBIC is smaller or equal to MIC, indicating
that LTS powder is equally or more efficient against adhered
cells, despite their much higher resistance to antibiotics in
comparison with their planktonic counterparts. These sig-
nificant results were also recorded for all the other MgB2
powders: (MBIC ¼ 0.15e1.25 mg/mL) < (MIC ¼ 0.62e2.5 mg/
mL). Powders PVZ, AA and CER show similar activity against P.es in planktonic (MIC) and biofilm (MBIC) growth states. SA
us ATCC 6538; Ps ¼ Pseudomonas aeruginosa ATCC 27853;
0231 (Ca).
Table 3 e MIC and MBIC values of the tested MgB2 powders against 29 methicillin resistant clinical S. aureus and 33
vancomycin resistant E. faecium/faecalis strains.
Powder Clinical, resistant S. aureus strains Clinical, resistant E. faecium/faecalis strains
Planktonic Biofilm Planktonic Biofilm
MIC (mg/mL) No. Strains MBIC (mg/mL) No. Strains MIC (mg/mL) No. Strains MBIC (mg/mL) No. Strains
LTS >2.5 4 >2.5 23 >2.5 11 >2.5 16
13.8% 79.3% 47.8% 69.6%
e e e e e e 1.25 1
e e e 4.3%
0.625 3 e e 0.625 2 0.625 2
10.3% e 8.7% 8.7%
0.3125 20 0.3125 5 0.3125 1 0.3125 3
69.0% 17.2% 4.3% 13.0%
0.156 2 0.156 1 0.156 3 0.156 1
6.9% 3.4% 13.0% 4.3%
e e e 0.078 4 e e
e e 17.4% e
e e e 0.039 2 e e
e e 8.7% e
PVZ >2.5 4 >2.5 20 >2.5 11 >2.5 14
13.8% 69.0% 47.8% 60.9%
0.625 15 0.625 7 0.625 1 0.625 3
51.7% 24.1% 4.3% 13.0%
0.3125 10 0.3125 2 0.3125 1 0.3125 2
34.5% 6.9% 4.3% 8.7%
e e e e 0.156 7 0.156 3
e e 30.4% 13.0%
e e e e 0.078 2 e e
e e 8.7% e
e e e e 0.039 1 0.039 1
e e 4.3% 4.3%
AA >2.5 4 >2.5 19 >2.5 11 >2.5 16
13.8% 65.5% 47.8% 69.6%
e e e e e e 1.25 1
e e e 4.3%
0.625 15 0.625 3 0.625 2
51.7% 10.3% 8.7%
0.3125 10 0.3125 5 0.3125 7 0.3125 3
34.5% 17.2% 30.4% 13.0%
e e 0.156 2 0.156 3 0.156 1
e 6.9% 13.0% 4.3%
e 0.078 2
8.7%
CER >2.5 4 >2.5 18 >2.5 11 >2.5 18
13.8% 62.1% 47.8% 78.3%
0.625 21 0.625 8 0.625 1 0.625 1
72.4% 27.6% 4.3% 4.3%
0.3125 4 0.3125 3 0.3125 5 0.3125 2
13.8% 10.3% 21.7% 8.7%
e e e e 0.156 5 0.156 2
e e 21.7% 8.7%
e e e e 0.078 1 e e
e e 4.3% e
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(MBIC ¼ MIC ¼ 0.62 mg/mL). The highest values of MIC and
MBIC (i.e. the lowest activity) were observed for powders PVZ
and CER regardless the microbial strain. MIC and MBIC were
measured for one set of experiments.
3.2.2. Antimicrobial activity of MgB2 powders against
clinical, resistant strains in planktonic and biofilm growth state
The assessment of the MIC values of MgB2 powders against 29
methicillin resistant clinical S. aureus isolates and 33vancomycin resistant E. faecium/faecalis strains (Table 3),
revealed that the most active powder against planktonic bac-
teria was LTS, similar to the results obtained for susceptible,
reference strains,with theMIC range from>2.5 to 0.156mg/mL
for S. aureus strains and in the range of >2.5 to 0.039 mg/mL E.
faecium/faecalis strains. In case of the anti-biofilm assays, the
most efficient powders were AA, followed by LTS, with MBIC
values in the range of >2.5 to 0.156 mg/mL for S. aureus strains
and PVZ for E. faecium/faecalis, with MBIC of >2.5 to 0.039 mg/
mL. We note that in this case, for the highest concentration
Fig. 6 e Images of optical microscopy on cell layers of HeLa stained with PI (red dead cells) and FDA (green viable cells) after
treatment with MgB2 powder solutions with concentrations of 10 and 100 mg/mL. (For interpretation of the references to
colour in this figure legend, the reader is referred to the Web version of this article.)
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strains that is resistant to the antimicrobial treatments is
higher for bacteria in the biofilm form compared to the ones in
the planktonic state. This situation reveals that for the resis-
tant strains, MgB2 powders show a lower activity against bio-
films, which is opposite to what happens for the reference
strains (see Section 3.2.1, Fig. 5).
Overall, the results from Section 3.2 indicate the significant
antimicrobial and anti-biofilm activity of MgB2 powders, with
a large spectrum including susceptible, as well as resistant
microbial isolates. The stronger inhibitory effect against bio-
films than on planktonic cells for reference strains is both
outstanding and surprising and deserves further attention in
the view of its significant fundamental and practical impact.
The highest activity was demonstrated by LTS followed by AA.
These two powders show the lowest tendencies to form large
agglomerates, particles surface is clean (low level of oxides)
and they have a high elemental purity (99.5% and 99%, Table
1). While LTS has the highest pH-increase rate, for AA sam-
ple it is intermediate (third) and, as anticipated, a direct cor-
relation of the antimicrobial efficiency with pH (Section 3.1) is
not sustained. Depending on different factors (powderFig. 7 e The effects induced by MgB2features, media, and cells type and state), the pH behavior
could vary in different anatomic locations, in physiological or
pathological conditions and this can be a positive aspect in
refining the control of the processes at the cells-NM interface.
3.3. MgB2 powders cytotoxicity and cell cycle analysis
The results of qualitative evaluation by optical microscopy of
MgB2 powders cytotoxicity on the HeLa cells are presented in
Fig. 6 (one set of experiments).Wenote that similar results (not
shown here) were obtained for HT-29 cell line. In the presence
ofMgB2 concentration of 100 mg/mL, the cellsmortality is 100%:
dead cells turn red because propidium iodide (PI) dye pene-
trates only cells with damaged membrane and intercalates
between DNA bases. In contrast, at a concentration of 10 mg/
mL (Fig. 6) the toxicity of MgB2 decreases: cells are viable and
green due to coloring in the presence of the vital FDA dye.
To elucidate the mechanism of the cytotoxic effect
observed at high MgB2 concentrations (100 mg/mL), the cell
cycle analysis for HeLa and HT-29 was performed (Fig. 7).
The phases of a eukaryotic cell cycle are Resting (phase G0),
Interphase (composed of phases G1, S, and G2) and Mitosis(100 mg/mL) on the cellular cycle.
Fig. 8 e (a) The average abundance (CFU/g) of E. coli in the liver (A), spleen (B), and peritoneal fluid (C) in nude CD-1 mice
infected with E. coli (group 2, Control, see Section 2.4) and infected with E. coli and treated with MgB2 (LTS) (group 4): n ¼ 4,
means ± standard error of the mean, unpaired t-test, in A p ¼ 0.12, B p < 0.01, and C p < 0.05; (b) The relative abundance of
different bacteria in the intestinal microbiota in healthy mice (group 1, Control) and in mice treated with MgB2 (group 3):
n ¼ 4, means ± standard error of the mean, unpaired t-test, for Enterobacteriaceae p ¼ 0.19, Lactobacillus sp. p ¼ 0.12,
Clostridium leptum p ¼ 0.13, Clostridium coccoides p ¼ 0.1, and Ruminococcus p ¼ 0.36.
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Interphase occupies 90% of the cell cycle duration, and in
this phase the biosynthesis of DNA, RNA, and proteins
necessary for cell division takes place, following three
steps: (a) G1 phase - transcription and protein synthesis,
chromatin decondensation, nucleolar reorganization; (b) S
phase - DNA replication; (c) G2 e continuation of the cell
growth. In the M phase, the cell divides into two daughter
cells. Each new cell will enter the interphase phase. Flow
cytometry assays using PI dye quantifies the percentage of
cells in different stages of the interphase. If a substance
interferes with the cell cycle, the appearance of dot blot
charts will change. The distinctive peaks known as subG1
or the G0/G1 peaks preceding G1 are characteristic for dead
cells. They are ascribed to apoptosis (peak 1) and necrosis
(peak 2) (Fig. 7). One observes in Fig. 7 that the four pow-
ders tested for a constant concentration of MgB2 (100 mg/
mL) induced the occurrence of a pro-apoptotic peak (peak
1), in the following decreasing order: LTS ¼ PVZ ¼ AA > CER
for HeLa and PVZ > LTS ¼ CER > AA for HT-29. The pow-
ders affect also phases S (DNA replication) or S þ G2 (DNA
replication and continuation of the cell growth) peaks. The
decreasing order is: AA > CER > LTS > PVZ for HeLa and
AA ¼ LTS > PVZ > CER for HT-29. The influence on the cell
cycle is revealed and it depends on powders and investi-
gated cells. LTS and AA powders take the top incidence
positions as the most active.
We shall also note that the powders mainly induce an ar-
rest of the tested tumor cells in the S phase: they interfere
with the DNA synthesis and thus, with the cellular prolifera-
tion. These effects could be exploited in the future for devel-
opment of novel anti-cancer drugs.
3.4. In vivo experiments assessing the anti-infectious
effect and the influence of MgB2 on intestinal microbiota
Considering that the best antimicrobial activity was exhibited
by the LTS powder, its anti-infectious potential was further
studied in an in vivo infectionmodel. The results are presented
in Fig. 8a. The MgB2 treatment led to a significant decrease ofthe pathogenic E. coli charge in liver, spleen, and peritoneal
liquid, demonstrating the powder efficiency for inhibiting the
E. coli invasion and multiplication in the host tissues.
The powder effect on mice intestinal microbiota has been
also investigated (Fig. 8b). It has been shown that MgB2 caused
changes in themicemicrobiota, mainly inducing higher levels
of Enterobacteriaceae and lower levels of Clostridium coccoides
comparatively to control. The abundance of lactobacilli in the
large intestine was diminished by MgB2. Lactobacilli play an
important role in maintaining the host mucosal homeostasis
against pathogens, by direct and indirect mechanisms,
including the production of hydrogen peroxide (H2O2). It has
been shown that lactobacilli inhibit the growth and biofilm
formation of C. albicans and cariogenic streptococci [94e98].
Balancing the microbiota with the help of MgB2 deserves
further attention since the microbiota is linked with multiple
immuno-oncological processes [99e101].4. Conclusion
In this study, we have selected four commercial MgB2 nano-
powders and evaluated them by a complex methodological
approach, using in vivo and in vitro assays, in order to propose
novel applications for these compounds in the biomedical
field. For this purpose, we have investigated their interaction
with microbial and tumor cells and tried to correlate the bio-
logical effects with specific physicalechemical properties of
the tested nanopowders, in an endeavor to open the avenue for
the development of novel antimicrobial and antitumor agents.
The tested MgB2 nanopowders show very different phase
contents, structural and microstructural details that influence
their physico-chemical properties, which, in turn, control their
interaction with microbes and tumor cells. In general, a higher
bioactivity against the indicated cells was found for powders
with the purity in the range of 95e99.5% showing a higher
MgB2 phase content, clean surfaces of the particles (less ox-
ides) and with a lower tendency for agglomeration. These
powders also show the highest pH-increase rate when
immersed in water. The fast increase of pH is determined to be
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the powders and microbes also contribute. The possibility of
controlled pH-increase-rate for the studied powders are
thought to open newopportunities in search of novel solutions
for space and time-scale controlled variation of the functional
properties required for different bio-applications.
One remarkable and surprising result is that for reference
microbial strains the minimal inhibitory concentration evalu-
ated in vitro for planktonicmicrobes is larger than that obtained
for biofilms. The higher antimicrobial efficiency of MgB2 on
biofilms thanonplanktonic cells deserves further attention and
requires more research. It is also important to note that our
tests indicate on good antimicrobial activity, not only on
referencebacterial andyeast strains, but also onclinical strains,
which are resistant tomethicillin or vancomycin, as in the case
of S. aureus and of E. faecium/faecalis strains, respectively.
Furthermore, results of antimicrobial activity of MgB2 powders
were confirmed in vivo on mice models infected with E. coli.
The cytotoxicity and cell cycle analysis on tumor cells
(HeLa and HT-29 lines) indicate that MgB2 inhibits their
growth especially affecting the S phase e the DNA synthesis.
In vivo experiments on mice have shown modification of in-
testinal microbiota inducing higher levels of Enterobacteriaceae
and lower levels of C. coccoides comparatively to control. These
experiments suggest that MgB2 is a useful candidate to be
explored for cancer and other diseases treatments.Author contributions statement
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